Comparative Pharmacology
Head-to-head clinical analysis: PREVACID versus PRILOSEC OTC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PREVACID versus PRILOSEC OTC.
PREVACID vs PRILOSEC OTC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Proton pump inhibitor (PPI) that irreversibly inhibits the H+/K+ ATPase enzyme (proton pump) in gastric parietal cells, thereby suppressing gastric acid secretion.
Proton pump inhibitor that irreversibly inhibits the H+/K+ ATPase enzyme (proton pump) in gastric parietal cells, suppressing gastric acid secretion.
15-30 mg orally once daily; or 30 mg orally twice daily for severe GERD.
20 mg orally once daily for 14 days for frequent heartburn; may repeat 14-day course every 4 months.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5 hours. No significant accumulation with once-daily dosing.
Approximately 0.5–1 hour in healthy subjects; longer (up to 3 hours) in slow metabolizers or hepatic impairment. Clinically, the duration of acid suppression exceeds the half-life due to accumulation in parietal cell canaliculi.
Renal (approx. 70% as metabolites), fecal (approx. 30% as metabolites). Less than 1% excreted unchanged in urine.
Primarily hepatic metabolism; about 80% of metabolites are excreted in urine, and the remainder in feces via bile. Less than 1% of unchanged drug is excreted in urine.
Category C
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor